the aid library

LIST OPTIONS

Filter

6464

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

Download (419)

View PDF (462)

The 2014 Myanmar Population and Housing Census: Thematic Report on Population Dynamics

The Republic of the Union of Myanmar (2016) C1

Census Report Volume 4-E
As no census has been undertaken in over 30 years, many aspects of the demographic situation in the country were unknown. For instance, before the Census it was thought that the country had a population of about 60 million, but the 2014 Census showed that the population... more

Download (346)

View PDF (478)

Blueprint for a Public Health and Safety Approach to Drug Policy

Tracy Pugh, Julie Netherland, Ruth Finkelstein The New York Academy of Medicine, Drug Policy Alliance (2013) C2

"Some of the problems with our current drug policies stem from the fact that these policies have been largely bifurcated between two different and often contradictory approaches. One treats drug use as a crime that cannot be tolerated and should be punished; the other views addiction as a chronic re... more

Download (270)

View PDF (530)

WHO Timor-Leste Country Cooperation Strategy: 2021-2025

World Health Organisation (WHO) (2023) C_WHO

In the last decade, Timor-Leste has made remarkable progress in strengthening its health system and improving the health status of its population. This has resulted in an increased life expectancy, and the achievement of Millennium Development Goals such as a reduction in infant and under-five morta... more

Download (459)

View PDF (692)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (494)

View PDF (615)

National Strategic Plan for Tuberculosis 2016-2020

The Republic of the Union of Myanmar, Ministry of Health and Sports (2016) C1

National Tuberculosis Programme
The National Strategic Plan (NSP) for Tuberculosis (TB) 2016-2020 builds on the past experiences for the National Tuberculosis Programme and its partners. This NSP provides a roadmap for delivering quality TB prevention and care service to the entire population, ... more

External Link

Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities

Bovet, P.; Chiolero, A.; Paccaud, F. et al. Public Health Reviews (2015) CC

Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of premature mortality in low and middle income countries (LMICs). Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector... more

Download (293)

View PDF (426)

Situation Analysis and Recommendation: Antibiotic Use and Resistance in Tanzania

Aboud S., R. Mdegela Global Antibiotic Resistance Partnership—Tanzania Working Group (2015) C2

Antibiotics and other antimicrobial agents are invaluable life savers, particularly in resource-limited countries where infectious diseases are abundant. Both uncomplicated and severe infections are potentially curable as long as the aetiological agents are susceptible to the ... more

Download (309)

View PDF (313)

United Nations COVID-19 Emergency Appeal Zambia (May - October 2020)

OCHA; UNCT Zambia (2020) C2

The Government of Republic of Zambia reported the first confirmed cases of COVID-19 on 18th March 2020. As of April 27th, 2020, there were 89 confirmed cases, three deaths and 42 recoveries. Confirmed cases are located in three provinces: Lusaka (83 cases), Copperbelt province (5 cases) and Central ... more

Download (199)

View PDF (196)

Health Technology MANUAL: Improving the Integrated Management of Chronic Diseases at the First Level of Health Care Services

Pan American Health Organization PAHO; World Health Organization WHO (2017) C_WHO

Care for persons with noncommunicable diseases (NCDs), such as cardiovascular disease, diabetes, cancer, and chronic obstructive pulmonary disease, is a major health priority for most countries worldwide, particularly for low-middle income countries where the problem seems to be worsening. Globally,... more

Download (430)

View PDF (418)

Rwanda 2014-15 Demographic and Health Survey - Key Findings

National Institute of Statistics of Rwanda (NISR) [Rwanda], Ministry of Health (MOH) [Rwanda], and ICF International (2016) C2

This report provides an overview of the Key findings of the Rwanda 2014-2015 Demographic and Health Survey (RDHS). The 2014-15 Rwanda Demographic and Health Survey (RDHS) was designed to provide data for monitoring the population and health situation in Rwanda. The 2014-15 RDHS is the fifth Demogra... more

Download (238)

View PDF (349)

Mitigating the impact of COVID-19 on countries affected by HIV, tuberculosis and malaria

Global fund (2020) CC

While many of the countries hit by the COVID-19 in the first few months of the year are now beginning to relax lockdown measures as infection and death rates fall, in the regions most affected by HIV, TB and malaria, such as Africa, South Asia and Latin America, the pandemic continues to accelerate.... more

Download (10417)

View PDF (10401)

Cholera Outbreak Guidelines Preparedness, Prevention and Control
recommended

Elizabeth Lamond, and Jesee Kinyanjui Oxfam (2012) C1

The Cholera Outbreak Guidelines: Preparedness, Prevention, and Control provide a practical field guide for responding to cholera outbreaks. Developed by Oxfam GB, the guidelines combine lessons from past cholera interventions and best practices for effective outbreak management. The document outline... more

Download (483)

View PDF (516)

Management of a cholera epidemic
recommended

Médecins sans Frontières MSF (2018) C1

Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians. The document is a comprehensive guide for managing cholera epidemics, providing detailed protocols for prevention, outbreak investigation, treatment, and control mea... more

Download (1582)

View PDF (1578)

Global update on HIV treatment 2013: Results, impact and opportunities

World Health Organization; UNICEF; UNAIDS (2013)

Chapter 1 provides new data on the latest developments in the global treatment effort, highlighting positive trends as well as aspects that require improvement. Chapter 2 summarizes the impact of the scale-up in reducing AIDS-related mortality and new HIV infections. Chapter 3 examines the sequence ... more

Download (218)

View PDF (245)

Open Access Re-envisioning Kangaroo Mother Care Implementation Through a Socioecological Model: Lessons From Malawi

Global Health: Science and Practice (2022) CC2

Kangaroo mother care (KMC) is a critical strategy to care for preterm and low birth weight infants in resource-limited settings. Despite evidence of its effectiveness and low cost, coverage has remained low, largely due to sociocultural barriers. We aimed to better understand social norms and commun... more

Download (205)

View PDF (231)

Fight for what counts. Investment Case

The Global Fund (2022) CC

Over the 20 years that followed, this unique partnership has invested more than US$53 billion, saving 44 million lives and reducing the combined death rate from the three diseases by more than half in the countries in which the Global Fund invests.

Download (963)

View PDF (3246)

Management of Buruli ulcer–HIV coinfection

World Health Organization WHO (2020) C_WHO

Technical Update Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection.... more

Download (434)

View PDF (636)

A short guide to cancer screening. Increase effectiveness, maximize benefits and minimize harm

World Health Organization WHO, Regional Office of Europe (2022) C1

The purpose of cancer screening tests is to detect pre-cancer or early-stage cancer in asymptomatic individuals so that timely diagnosis and early treatment can be offered, where this treatment can lead to better outcomes for some people. The aim of a cancer screening programme is either to reduc... more

Cholera Outbreak Guidelines Preparedness, Prevention and Control recommended

Management of a cholera epidemic recommended

Cholera Outbreak Guidelines Preparedness, Prevention and Control
recommended

Management of a cholera epidemic
recommended